Author

Marie-Clémence Verdier

SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?
SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?

Marie-Clémence Verdier  et al.

Item 1 - 1 / 1
1